Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
partial response
Description:
A clinical outcome indicating that a disease or its measurable signs have improved with treatment without meeting criteria for complete response.
OpenAlex ID:
keywords/partial-response
Response criteria for phase II studies of supratentorial malignant glioma.
1990
·
D R Macdonald
, T L Cascino
, et al.
·
Journal of Clinical Oncology
·
2,414
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
1999
·
Michael B. Atkins
, Michael T. Lotze
, et al.
·
Journal of Clinical Oncology
·
2,074
RECIST 1.1—Update and clarification: From the RECIST committee
2016
·
Lawrence H. Schwartz
, Saskia Litière
, et al.
·
European Journal of Cancer
·
2,032
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
1995
·
G Fyfe
, R I Fisher
, et al.
·
Journal of Clinical Oncology
·
1,408
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
2014
·
A. Keith Stewart
, S. Vincent Rajkumar
, et al.
·
New England Journal of Medicine
·
1,375
PDF
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
2019
·
O. Hamid
, C. Robert
, et al.
·
Annals of Oncology
·
982
PDF
KIT as a Therapeutic Target in Metastatic Melanoma
2011
·
Richard D. Carvajal
, Cristina R Antonescu
, et al.
·
JAMA
·
905
Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies
2016
·
Denise M. Adams
, Cameron C. Trenor
, et al.
·
PEDIATRICS
·
890
Crizotinib in ALK -Rearranged Inflammatory Myofibroblastic Tumor
2010
·
James E. Butrynski
, David R. D'Adamo
, et al.
·
New England Journal of Medicine
·
881
Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
2000
·
J. Bonneterre
, B. Thürlimann
, et al.
·
Journal of Clinical Oncology
·
843
Matched-Transmission Technique for Channels With Intersymbol Interference
1972
·
H. Harashima
, H. Miyakawa
·
IRE Transactions on Communications Systems
·
824
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
2004
·
S. Jagannath
, B. Barlogie
, et al.
·
British Journal of Haematology
·
732
MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
2016
·
Mark M. Awad
, Geoffrey R. Oxnard
, et al.
·
Journal of Clinical Oncology
·
730
PDF
A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization
2009
·
R.J. Lewandowski
, L.M. Kulik
, et al.
·
American Journal of Transplantation
·
591
Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report
2006
·
Steven Z. Pavletic
, Paul Martin
, et al.
·
Transplantation and Cellular Therapy
·
569
PDF
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
2020
·
Michael R Migden
, Nikhil I Khushalani
, et al.
·
The Lancet Oncology
·
535
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
2014
·
Stefan Zeuzem
, Ira M. Jacobson
, et al.
·
New England Journal of Medicine
·
529
PDF
Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
2008
·
Franck Morschhauser
, John Radford
, et al.
·
Journal of Clinical Oncology
·
467
A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma
1985
·
Katsutaro Shimaoka
, David A. Schoenfeld
, et al.
·
Cancer
·
464
PDF
Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report
2015
·
Stephanie J. Lee
, Daniel Wolff
, et al.
·
Transplantation and Cellular Therapy
·
458
PDF
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.
2000
·
R I Fisher
, S A Rosenberg
, et al.
·
PubMed
·
439
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
2005
·
Sundar Jagannath
, Brian G. M. Durie
, et al.
·
British Journal of Haematology
·
398
Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group
1988
·
Bruce D. Cheson
, John M. Bennett
, et al.
·
American Journal of Hematology
·
397
Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial
2020
·
Ana Oaknin
, Anna V. Tinker
, et al.
·
JAMA Oncology
·
381
PDF
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
2016
·
Julie N. Graff
, Joshi J. Alumkal
, et al.
·
Oncotarget
·
372
PDF
Show more works
View as search
Works count:
4,299
Citation count:
89,150
Year
Topic
Type